QTTB · Q32 Bio Inc. Common Stock
View on chartInsiders & Stakes
| ORBIMED ADVISORS LLC Director | ▲ Buy | Open Market | 625,000 Shares held | 5/28/2026 | View profile |
| Xu Diyong Director | ▲ Buy | Open Market | 625,000 Shares held | 5/28/2026 | View profile |
| Morrison Jodie Pope CEO | ▼ Sell | Open Market | 343,259 Shares held | 8/25/2026 | View profile |
| Seymour Albert Chief Scientific Officer | ▼ Sell | Open Market | 150,874 Shares held | 9/6/2023 | View profile |
| Kalowski Lee CFO and President | ▼ Sell | Open Market | 138,471 Shares held | 8/25/2026 | View profile |
| Violette Shelia M. Chief Scientific Officer | ▼ Sell | Open Market | 127,771 Shares held | 8/25/2026 | View profile |
| Isaac Manke Director | ▲ Buy | Option Exercise | 53,521 Shares held | 6/30/2026 | View profile |
| Alloway Paul See Remarks | ▲ Buy | Option Exercise | 51,566 Shares held | 3/25/2024 | View profile |
| Campagna Jason Chief Medical Officer | ▲ Buy | Grant | 37,500 Shares held | 2/24/2025 | View profile |
| Michaud Charles Jr See Remarks | ▲ Buy | Option Exercise | 18,046 Shares held | 3/25/2024 | View profile |
| Smith W Bradford CFO & Treasurer | ▼ Sell | Open Market | 14,219 Shares held | 1/9/2023 | View profile |
| Blum Michael Lee Chief Commercial Officer | ▼ Sell | Open Market | 13,538 Shares held | 1/9/2023 | View profile |
| Arthur Tzianabos President & CEO | ▼ Sell | Open Market | 7,983 Shares held | 3/25/2024 | View profile |
| Jordan Julie Chief Medical Officer | ▼ Sell | Open Market | 7,496 Shares held | 8/3/2023 | View profile |
| Cohn Gabriel Chief Medical Officer | ▼ Sell | Open Market | 2,629 Shares held | 1/5/2022 | View profile |
| Timothy P. Kelly See Remarks. | ▼ Sell | Open Market | 2,224 Shares held | 1/5/2022 | View profile |
Transaction History
| Morrison Jodie Pope | ▼ Sell | Open Market | 9,845 | $163K | 8/25/2026 |
| Kalowski Lee | ▼ Sell | Open Market | 3,972 | $66K | 8/25/2026 |
| Violette Shelia M. | ▼ Sell | Open Market | 2,798 | $46K | 8/25/2026 |
| Kalowski Lee | ▲ Buy | Grant | 53,250 | $0 | 7/16/2026 |
| Violette Shelia M. | ▲ Buy | Grant | 37,500 | $0 | 7/16/2026 |
| Morrison Jodie Pope | ▲ Buy | Grant | 132,000 | $0 | 7/16/2026 |
| Isaac Manke | ▲ Buy | Option Exercise | 53,521 | $150K | 6/30/2026 |
| Xu Diyong | ▲ Buy | Open Market | 1,250,000 | $10.0M | 5/28/2026 |
| Xu Diyong | ▲ Buy | Open Market | 625,000 | $5.0M | 5/28/2026 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 1,250,000 | $10.0M | 5/28/2026 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 625,000 | $5.0M | 5/28/2026 |
| Kalowski Lee | ▼ Sell | Open Market | 3,995 | $18K | 2/25/2026 |
| Morrison Jodie Pope | ▼ Sell | Open Market | 9,896 | $45K | 2/25/2026 |
| Violette Shelia M. | ▼ Sell | Open Market | 2,815 | $13K | 2/25/2026 |
| Kalowski Lee | ▲ Buy | Grant | 53,250 | $0 | 2/24/2026 |
| Morrison Jodie Pope | ▲ Buy | Grant | 132,000 | $0 | 2/24/2026 |
| Violette Shelia M. | ▲ Buy | Grant | 37,500 | $0 | 2/24/2026 |
| Morrison Jodie Pope | ▼ Sell | Open Market | 22,506 | $78K | 12/2/2025 |
| Kalowski Lee | ▼ Sell | Open Market | 9,072 | $31K | 12/2/2025 |
| Morrison Jodie Pope | ▼ Sell | Open Market | 10,494 | $19K | 8/26/2025 |
| Violette Shelia M. | ▼ Sell | Open Market | 2,990 | $5K | 8/26/2025 |
| Kalowski Lee | ▼ Sell | Open Market | 4,240 | $8K | 8/26/2025 |
| Violette Shelia M. | ▲ Buy | Grant | 37,500 | $0 | 2/24/2025 |
| Campagna Jason | ▲ Buy | Grant | 37,500 | $0 | 2/24/2025 |
| Morrison Jodie Pope | ▲ Buy | Grant | 132,000 | $0 | 2/24/2025 |
| Kalowski Lee | ▲ Buy | Grant | 53,250 | $0 | 2/24/2025 |
| Violette Shelia M. | ▲ Buy | Option Exercise | 6,000 | $44K | 10/15/2024 |
| Violette Shelia M. | ▲ Buy | Option Exercise | 4,574 | $14K | 10/11/2024 |
| Violette Shelia M. | ▲ Buy | Option Exercise | 13,300 | $41K | 10/8/2024 |
| Alloway Paul | ▼ Sell | Open Market | 268 | $6K | 3/25/2024 |
| Michaud Charles Jr | ▼ Sell | Open Market | 75 | $2K | 3/25/2024 |
| Alloway Paul | ▲ Buy | Option Exercise | 23,530 | — | 3/25/2024 |
| Michaud Charles Jr | ▲ Buy | Option Exercise | 6,448 | — | 3/25/2024 |
| Arthur Tzianabos | ▲ Buy | Option Exercise | 1,095 | — | 3/25/2024 |
| Arthur Tzianabos | ▼ Sell | Open Market | 265 | $6K | 3/25/2024 |
| Arthur Tzianabos | ▼ Sell | Open Market | 13,037 | $7K | 1/9/2024 |
| Alloway Paul | ▼ Sell | Open Market | 7,280 | $4K | 1/3/2024 |
| Michaud Charles Jr | ▼ Sell | Open Market | 1,708 | $975 | 1/3/2024 |
| Arthur Tzianabos | ▲ Buy | Option Exercise | 14,280 | — | 1/1/2024 |
| Arthur Tzianabos | ▲ Buy | Option Exercise | 19,140 | — | 1/1/2024 |
| Alloway Paul | ▲ Buy | Option Exercise | 4,420 | — | 1/1/2024 |
| Alloway Paul | ▲ Buy | Option Exercise | 5,280 | — | 1/1/2024 |
| Alloway Paul | ▲ Buy | Option Exercise | 8,910 | — | 1/1/2024 |
| Michaud Charles Jr | ▲ Buy | Option Exercise | 544 | — | 1/1/2024 |
| Michaud Charles Jr | ▲ Buy | Option Exercise | 1,056 | — | 1/1/2024 |
| Michaud Charles Jr | ▲ Buy | Option Exercise | 2,640 | — | 1/1/2024 |
| Seymour Albert | ▲ Buy | Option Exercise | 4,620 | — | 9/6/2023 |
| Seymour Albert | ▼ Sell | Open Market | 1,448 | $2K | 9/6/2023 |
| Jordan Julie | ▲ Buy | Option Exercise | 387 | $0 | 8/3/2023 |
| Jordan Julie | ▼ Sell | Open Market | 109 | $152 | 8/3/2023 |
| Jordan Julie | ▲ Buy | Option Exercise | 4,644 | $0 | 8/3/2023 |
| Jordan Julie | ▼ Sell | Open Market | 1,308 | $2K | 8/3/2023 |
| Jordan Julie | ▲ Buy | Option Exercise | 1,548 | $0 | 8/3/2023 |
| Jordan Julie | ▼ Sell | Open Market | 436 | $606 | 8/3/2023 |
| Jordan Julie | ▲ Buy | Option Exercise | 350 | $0 | 8/2/2023 |
| Jordan Julie | ▼ Sell | Open Market | 99 | $130 | 8/2/2023 |
| Alloway Paul | ▼ Sell | Open Market | 10,965 | $16K | 3/2/2023 |
| Blum Michael Lee | ▼ Sell | Open Market | 2,454 | $3K | 1/9/2023 |
| Alloway Paul | ▼ Sell | Open Market | 3,090 | $4K | 1/9/2023 |
| Seymour Albert | ▼ Sell | Open Market | 3,620 | $5K | 1/9/2023 |
| Arthur Tzianabos | ▼ Sell | Open Market | 10,616 | $15K | 1/9/2023 |
| Smith W Bradford | ▼ Sell | Open Market | 3,729 | $5K | 1/9/2023 |
| Blum Michael Lee | ▲ Buy | Option Exercise | 2,640 | — | 1/1/2023 |
| Blum Michael Lee | ▲ Buy | Option Exercise | 4,950 | — | 1/1/2023 |
| Arthur Tzianabos | ▲ Buy | Option Exercise | 13,860 | — | 1/1/2023 |
| Arthur Tzianabos | ▲ Buy | Option Exercise | 19,140 | — | 1/1/2023 |
| Seymour Albert | ▲ Buy | Option Exercise | 4,290 | — | 1/1/2023 |
| Seymour Albert | ▲ Buy | Option Exercise | 6,930 | — | 1/1/2023 |
| Smith W Bradford | ▲ Buy | Option Exercise | 6,600 | — | 1/1/2023 |
| Smith W Bradford | ▲ Buy | Option Exercise | 6,930 | — | 1/1/2023 |
| Alloway Paul | ▲ Buy | Option Exercise | 4,290 | — | 1/1/2023 |
| Alloway Paul | ▲ Buy | Option Exercise | 5,280 | — | 1/1/2023 |
| Smith W Bradford | ▼ Sell | Open Market | 2,182 | $8K | 1/5/2022 |
| Timothy P. Kelly | ▼ Sell | Open Market | 1,406 | $5K | 1/5/2022 |
| Seymour Albert | ▼ Sell | Open Market | 1,661 | $6K | 1/5/2022 |
| Cohn Gabriel | ▼ Sell | Open Market | 1,661 | $6K | 1/5/2022 |
| Arthur Tzianabos | ▼ Sell | Open Market | 5,354 | $20K | 1/5/2022 |
| Smith W Bradford | ▲ Buy | Option Exercise | 6,600 | — | 1/1/2022 |
| Timothy P. Kelly | ▲ Buy | Option Exercise | 3,630 | — | 1/1/2022 |
| Seymour Albert | ▲ Buy | Option Exercise | 4,290 | — | 1/1/2022 |
| Cohn Gabriel | ▲ Buy | Option Exercise | 4,290 | — | 1/1/2022 |
| Arthur Tzianabos | ▲ Buy | Option Exercise | 13,860 | — | 1/1/2022 |
| Timothy P. Kelly | ▼ Sell | Open Market | 54 | $416 | 9/3/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Q32 Bio to Present Late‑Breaking Results of Bempikibart Trial at EADV Congress
Q32 Bio will present late‑breaking results from Part B of its SIGNAL‑AA Phase 2a study of Bempikibart for alopecia areata at the European Academy of Dermatology and Venereology Congress. The company also shared additional 36‑week data from the same study earlier in the congress. These updates provide new information on the drug’s safety and efficacy profile, which may influence market perception of the company’s pipeline.
Q32 Bio to Present Late‑Breaking Results of Bempikibart Trial at EADV Congress. Q32 Bio will present late‑breaking results from Part B of its SIGNAL‑AA Phase 2a study of Bempikibart for alopecia areata at the European Academy of Dermatology and Venereology Congress. The company also shared additional 36‑week data from the same study earlier in the congress. These updates provide new information on the drug’s safety and efficacy profile, which may influence market perception of the company’s pipeline.